



AWTTC

All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

The New Treatment Fund

**Medicines Recommended by NICE and AWMSG:
Health Board Formulary Status
(From 1 January 2019 to 31 December 2019)**

BACKGROUND

The Welsh Government launched the New Treatment Fund in January 2017. The fund provides an additional £16 million annually for health boards and trusts in Wales to support the faster introduction of new medicines recommended by the National Institute for Health and Care Excellence (NICE) and the All Wales Medicines Strategy Group (AWMSG).

The New Treatment Fund requires the seven health boards and one NHS trust to make recommended medicines available as soon as is reasonably practicable and certainly within 60 days of the publication of the decision. For NICE recommendations, a medicine should be available no later than 60 calendar days after the first publication of the Final Appraisal Determination (FAD), or the Final Evaluation Determination (FED) for Highly Specialised Technologies (HSTs). For AWMSG recommendations, a medicine should be available no later than 60 calendar days after ratification of the recommendation by the Welsh Government. Occasionally the start of the 60 day timescale may be delayed because a Commercial Access Agreement (CAA) has not yet been agreed. In such circumstances this is indicated within the report. NICE and AWMSG may recommend an entirely new medicine, or a new use of an existing medicine to treat a different condition, for routine use in the NHS. Although recommended medicines should be made available within 60 days of recommendation, the sooner they are available, the sooner they can be prescribed where clinically appropriate.

In April 2017 the Welsh Government issued revised directions for health boards and NHS trusts, with an accompanying Welsh Health Circular, *The New Treatment Fund – Access to medicines recommended by NICE and AWMSG* (WHC [2017] 001).

A health board formulary is an official list of medicines which may be prescribed within the health board to treat patients. Until a medicine is added to the formulary, prescribers may not be aware that it is available for use.

This document reports on the formulary status of medicines recommended for use within NHS Wales by NICE and AWMSG. All medicines listed in this report were recommended between 1st January 2019 and 31st October 2019. All data in this report is as of 31st December 2019.

SOURCE OF INFORMATION

Across Wales, the health boards use the online “Inform” formulary software programme provided and maintained by the NHS Wales Informatics Service (NWIS). Velindre NHS Trust treats certain types of cancers only; the report therefore only takes account of those medicines clinically appropriate for inclusion on the trust formulary.

This report has been compiled through a combination of an analysis of health board formularies and the submission of data and additional information from Chief Pharmacists.

Table 1. Formulary status and time elapsed since latest AWMMSG/NICE recommendation for New Treatment Fund medicines (31 December 2019)

Appraisal Approval Date	CAA Available Date [¥]	AWMSG or NICE ref	Medicine Name	Abbreviated Indication	Health Board formulary status ^{^#}						
					Aneurin Bevan	BCU	C&V	CTM	Hywel Dda	Powys	SB
04/01/19		ID1129 (TA565)	Benralizumab	Asthma	6	18	34	20	34	40	0
17/01/19		ID1227 (TA563)	Abemaciclib	Breast cancer	11	8	49	7	21	27	0
18/01/19		ID1097 (TA561)	Venetoclax	Leukaemia	7	7	48	10	20	26	0
18/01/19		ID923 (TA562)	Encorafenib	Melanoma	3	4	48	6	20	26	0
18/01/19		ID923 (TA562)	Binimetinib	Melanoma	3	4	48	6	20	26	0
15/02/19		ID1192 (TA569)	Pertuzumab	Breast cancer	3	7	48	3	21	32	4
15/02/19		ID1328 (TA571)	Brigatinib	Lung cancer	5	7	48	7	21	32	0
21/02/19		ID1158 (TA572)	Ertugliflozin	Diabetes	7	14	42	11	15	26	0
05/03/19		3103	Romiplostim	Chronic idiopathic thrombocytopenic purpura	6	8	30	6	3	14	0
05/03/19		2908	Ciclosporin	Conjunctivitis	6	8	30	6	3	14	0
08/03/19		ID1232 (TA574)	Certolizumab	Psoriasis	3	5	27	3	0	11	0
08/03/19		ID1060 (TA575)	Tildrakizumab	Psoriasis	3	5	27	3	7	11	0
12/03/19	25/04/19	ID974 (TA573)	Daratumumab	Multiple myeloma	1	7	42	105	20	6	0
21/03/19		ID1190 (TA577)	Brentuximab vedotin	Lymphoma	11	21	42	8	55	7	0
28/03/19	22/07/19	ID1175 (TA578)	Durvalumab	Lung cancer	4	4	45	1	0	1	0
28/03/19		3911	Ataluren	Muscular dystrophy	12	14	35	12	48	34	0
28/03/19		1514	Dasatinib	Leukaemia	12	14	35	12	48	34	0
02/04/19	30/05/19	ID1339 (TA579)	Abemaciclib	Breast cancer	0	27	35	21	20	29	0
05/04/19	05/04/19	ID1182 (TA581)	Nivolumab	Renal cancer	4	6	27	4	41	26	0
05/04/19	05/04/19	ID1182 (TA581)	Ipilimumab	Renal cancer	4	6	27	4	41	26	0
12/04/19		3769	Blinatumomab	Leukaemia	5	20	55	25	34	19	0
12/04/19		3750	Mepolizumab	Asthma	3	20	55	25	34	19	0
16/04/19		ID1242 (HST9)	Inotersen	Amyloidosis	10	23	51	21	30	15	0
02/05/19		ID1210 (TA584)	Atezolizumab	Lung cancer	6	7	35	5	14	14	0
09/05/19	12/07/19	ID938 (TA585)	Ocrelizumab	Multiple sclerosis	3	11	118	11	0	11	24
17/05/19		ID474 (TA587)	Lenalidomide	Multiple myeloma	-	7	7	-	33	21	0
17/05/19		ID667 (TA586)	Lenalidomide	Multiple myeloma	-	7	7	-	33	21	0
30/05/19		ID1153 (TA591)	Letermovir	Cytomegalovirus	1	4	35	4	20	8	0
06/06/19		ID1160 (TA583)	Ertugliflozin	Diabetes	0	1	56	1	13	1	-
11/06/19		2777	Fingolimod	Multiple sclerosis	3	15	51	9	8	17	-
20/06/19		ID1039 (TA590)	Fluocinolone acetonide intravitreal implant	Uveitis	0	8	42	5	60	8	-
25/06/19		991	Rufinamide	Epilepsy	7	3	-	-	59	3	0
25/06/19		1214	Eslicarbazepine acetate	Epilepsy	7	3	-	-	59	3	0
02/07/19	01/08/19	ID1367 (TA592)	Cemiplimab	Skin cancer	15	15	35	19	1	26	0
03/07/19	03/07/19	ID1069 (TA588)	Nusinersen	Spinal muscular atrophy	5	8	29	0	30	20	0
05/07/19		ID1346 (TA595)	Dacomitinib	Lung cancer	19	20	27	21	28	33	0
08/07/19		ID1279 (HST10)	Patisiran	Amyloidosis	16	17	59	18	25	30	0

Appraisal Approval Date	CAA Available Date*	AWMSG or NICE ref	Medicine Name	Abbreviated Indication	Health Board formulary status ^#						
					Aneurin Bevan	BCU	C&V	CTM	Hywel Dda	Powys	SB
12/07/19		ID1478 (TA597)	Dapagliflozin	Diabetes	3	11	55	11	59	11	0
12/07/19		ID1398 (TA596)	Risankizumab	Psoriasis	12	13	55	14	59	26	0
15/07/19		ID1036 (TA589)	Blinatumomab	Leukaemia	0	8	52	8	57	8	0
17/07/19	30/08/19	ID1318 (TA593)	Ribociclib	Breast cancer	7	3	34	0	27	14	0
26/07/19	21/11/19	ID1124 (TA598)	Olaparib	Ovarian, fallopian tube or peritoneal cancer	26	7	40	6	8	13	0
26/07/19		ID1293 (TA599)	Sodium zirconium cyclosilicate	Hyperkalaemia	0	19	41	10	55	12	-
31/07/19		ID1397 (TA607)	Rivaroxaban	Atherothrombotic events	0	82	36	-	57	7	-
08/08/19	19/09/19	ID1306 (TA600)	Pembrolizumab	Lung cancer	34	41	49	47	0	57	0
04/09/19		ID1054 (HST11)	Voretigene neparvovec	Inherited retinal dystrophies	118	28	29	5	22	48	118
05/09/19		ID1150 (TA605)	Clostridium botulinum neurotoxin type A	Chronic sialorrhoea	12	27	28	-	57	60	0
16/09/19		3977	Buprenorphine	Opioid dependence	2	16	52	14	0	17	0
18/09/19		ID1268 (TA606)	Lanadelumab	Hereditary angioedema	0	14	50	12	8	15	36
10/10/19		ID1364 (TA610)	Pentosan polysulfate sodium	Bladder pain syndrome	0	-	56	1	13	15	-
17/10/19		ID981 (TA612)	Neratinib	Breast cancer	33	13	49	7	7	8	0
23/10/19		4130	Zanamivir	Influenza	8	7	43	1	9	2	0
23/10/19		3917	Glecaprevir/pibrentasvir	Hepatitis C	8	7	43	1	9	2	0

* Time to formulary addition from appraisal approval date should be within two months for AWMSG Health Technology Appraisals (including the orphan and ultra-orphan appraisal process), NICE Health Technology Appraisals and HSTs and cancer drugs. For NICE recommendations these should be following the first publication of the FAD or the FED for HSTs, and for AWMSG approvals following Welsh Government ratification.

^ Number of days from latest AWMSG/NICE approval statements and formulary status are data submitted by health board/trust. Where no number is provided this can generally be assumed to indicate that the medicine is "already on formulary" but for a different indication. However this is not always the case.

The determination of formulary status is considered as the availability of the medicine to treat patients.

* CAA (Commercial Access Agreement) available date information is provided by the all Wales Medicines Procurement Specialist Pharmacist





Key		On formulary. Where a number is stated this represents the number of days from AWMSG/NICE approval to formulary addition. '-' indicates that the medicine is already on formulary for the appraised indication. '['] indicates a medicine has been added to formulary in advance of the CAA being agreed; stated number is number of days from AWMSG/NICE approval.
		On formulary. However the number of days stated is outside of the 60 day timescale.
		Not on formulary and within 60 days of approval date. Stated number is the number of days from AWMSG/NICE approval to 31 December 2019.
		Not on formulary and outside of 60 days since approval date. Stated number is the number of days from AWMSG/NICE approval to 31 December 2019.

Table 2. Velindre Cancer Centre medicines status

Appraisal Approval Date	CAA Available Date	AWMSG or NICE ref	Medicine name	Abbreviated indication	Health Board formulary status					
					C&V	Powys*	SB*	CTM	Aneurin Bevan	VCC ONLY
17/01/19		ID1227 (TA563)	Abemaciclib	Breast cancer	41	41	41	41	41	41
18/01/19		ID923 (TA562)	Encorafenib	Melanoma	40	40	40	40	40	40
18/01/19		ID923 (TA562)	Binimetinib	Melanoma	40	40	40	40	40	40
15/02/19		ID1192 (TA569)	Pertuzumab	Breast cancer	44	44	44	44	44	44
15/02/19		ID1328 (TA571)	Brigatinib	Lung cancer	**	44	12	12	12	12
28/03/19	22/07/19	ID1175 (TA578)	Durvalumab	Lung cancer	**	0	0	0	0	0
02/04/19	30/05/19	ID1339 (TA579)	Abemaciclib	Breast cancer	0	0	0	0	0	0
05/04/19	05/04/19	ID1182 (TA581)	Nivolumab	Renal cancer	17	17	17	17	17	17
05/04/19	05/04/19	ID1182 (TA581)	Ipilimumab	Renal cancer	17	17	17	17	17	17
02/05/19		ID1210 (TA584)	Atezolizumab	Lung cancer	**	47	47	47	47	47
02/07/19	01/08/19	ID1367 (TA592)	Cemiplimab	Skin cancer	20	20	20	20	20	20
05/07/19		ID1346 (TA595)	Dacomitinib	Lung cancer	47	47	47	47	47	47
17/07/19	30/08/19	ID1318 (TA593)	Ribociclib	Breast cancer	0	0	0	0	0	0
26/07/19	21/11/19	ID1124 (TA598)	Olaparib	Ovarian, fallopian tube or peritoneal cancer	26	26	26	26	26	26
08/08/19	19/09/19	ID1306 (TA600)	Pembrolizumab	Lung cancer	**	34	34	34	34	34
17/10/19		ID981 (TA612)	Neratinib	Breast cancer	33	33	33	33	33	33

*Powys and Swansea Bay also commission cancer services from other cancer providers. These dates relate to the Powys and Swansea Bay populations that Velindre Cancer Centre are commissioned for and there may be variability with dates from other cancer service providers.

** Cardiff and Vale have their own lung service.

Key		On formulary. Where a number is stated this represents the number of days from AWMSG/NICE approval to formulary addition. '-' indicates that the medicine is already on formulary for the appraised indication. '[]' indicates a medicine has been added to formulary in advance of the CAA being agreed; stated number is number of days from AWMSG/NICE approval.
		On formulary. However the number of days stated is outside of the 60 day timescale.
		Not on formulary and within 60 days of approval date. Stated number is the number of days from AWMSG/NICE approval to 31 December 2019.
		Not on formulary and outside of 60 days since approval date. Stated number is the number of days from AWMSG/NICE approval to 31 December 2019.